Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPD1 | P10809 | 1/20 | 0.72 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.72 |
| ▸ | IGF1R | P08069 | 4/20 | 0.67 |
| ▸ | INSR | P06213 | 2/20 | 0.67 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.64 |
| ▸ | CLK1 | P49759 | 1/20 | 0.64 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.64 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3904211 | 1.00 | HSPD1 (0.72) | HSPD1HSPE1IGF1RINSRCSNK2A2 | |
| SCHEMBL623839 | 0.86 | PIK3CG (0.82) | HSPD1HSPE1IGF1RINSRGSK3B | |
| SCHEMBL623840 | 0.86 | PIK3CG (0.82) | HSPD1HSPE1IGF1RINSRGSK3B | |
| SCHEMBL623841 | 0.86 | PIK3CG (0.82) | HSPD1HSPE1IGF1RINSRGSK3B | |
| SCHEMBL13388762 | 0.86 | IGF1R (0.72) | HSPD1HSPE1IGF1RINSRGSK3B | |
| SCHEMBL6388205 | 0.85 | HSPD1 (0.65) | HSPD1HSPE1IGF1RINSRCLK1 | |
| SCHEMBL6388201 | 0.85 | HSPD1 (0.65) | HSPD1HSPE1IGF1RINSRCLK1 | |
| SCHEMBL3904134 | 0.84 | IGF1R (0.72) | HSPD1HSPE1IGF1RINSRGSK3B | |
| SCHEMBL3897382 | 0.84 | IGF1R (0.79) | HSPD1HSPE1IGF1RINSRPIK3CG | |
| SCHEMBL3904132 | 0.84 | IGF1R (0.72) | HSPD1HSPE1IGF1RINSRGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004043955-A1 | RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | HSPD1 1909/4885HSPE1 1668/4885IGF1R 1698/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | HSPD1 2657/4885HSPE1 2257/4885IGF1R 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.